Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

Published:2021-12-14 Issue: Volume: Page:
ISSN:2688-4526
Container-title:BJUI Compass
language:en
Short-container-title:BJUI Compass

Author:

Anton Angelyn¹²³^ORCID,Pillai Sruti⁴,Semira Marie Christine¹,Wong Shirley⁵,Shapiro Julia⁶,Weickhardt Andrew⁴,Azad Arun⁷^ORCID,Kwan Edmond M.³⁸,Spain Lavinia²⁸,Gunjur Ashray⁴,Torres Javier⁹,Parente Phillip²⁸,Parnis Francis¹⁰¹¹,Goh Jeffrey¹²,Baenziger Olivia¹,Gibbs Peter¹⁵,Tran Ben¹⁷

Affiliation:

1. Division of Personalised Medicine Walter and Eliza Hall Institute Melbourne Victoria Australia

2. Department of Medical Oncology Eastern Health Melbourne Victoria Australia

3. Department of Medical Oncology Monash Health Melbourne Victoria Australia

4. Department of Medical Oncology Olivia Newton‐John Cancer and Wellness and Research Centre Melbourne Victoria Australia

5. Department of Medical Oncology Western Health Melbourne Victoria Australia

6. Alfred Health Melbourne Victoria Australia

7. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia

8. Faculty of Medicine, Nursing and Health Sciences Monash University Melbourne Victoria Australia

9. Department of Medical Oncology Goulburn Valley Health Shepparton Victoria Australia

10. Department of Medical Oncology Adelaide Cancer Centre Adelaide South Australia Australia

11. Faculty of Health and Medical Sciences University of Adelaide Adelaide South Australia Australia

12. Department of Medical Oncology Royal Brisbane and Women's Hospital Brisbane Queensland Australia

Funder

Astellas Pharma

Janssen Pharmaceuticals

Amgen

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

Religious studies,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bco2.129

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018

2. ESMO international consortium study on the availability, out‐of‐pocket costs and accessibility of antineoplastic medicines in countries outside of Europe;Cherny NI;Ann Oncol,2017

3. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real‐world' consideration of results from the advanced prostate Cancer consensus conference (APCCC) 2017;Chiong E;BJU Int,2019

4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‐naive men with metastatic castration‐resistant prostate cancer (COU‐AA‐302): Final overall survival analysis of a randomised, double‐blind, placebo‐controlled phase 3 study;Ryan CJ;Lancet Oncol,2015

5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer TM;N Engl J Med,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors;JCO Oncology Practice;2024-09

2. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial;Nature Medicine;2024-08-20

3. Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer;Cancers;2024-07-12

4. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26

5. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27